Acromegaly: a clinical perspective

Abstract Background To examine the clinical and hormonal profiles, comorbidities, treatment patterns, surgical pathology and clinical outcomes of patients diagnosed with acromegaly at the Cleveland Clinic over a 15-year period. Methods A retrospective chart review of patients with acromegaly who und...

Full description

Bibliographic Details
Main Authors: Lima Lawrence, Kenda Alkwatli, James Bena, Richard Prayson, Varun Kshettry, Pablo Recinos, Betul Hatipoglu, Kevin M. Pantalone, Robert Weil, Amir H. Hamrahian, Laurence Kennedy, Divya Yogi-Morren
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Clinical Diabetes and Endocrinology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40842-020-00104-5
id doaj-cb73a5e9408f4ff7bf7df21179dbb8f9
record_format Article
spelling doaj-cb73a5e9408f4ff7bf7df21179dbb8f92020-11-25T03:01:41ZengBMCClinical Diabetes and Endocrinology2055-82602020-08-01611910.1186/s40842-020-00104-5Acromegaly: a clinical perspectiveLima Lawrence0Kenda Alkwatli1James Bena2Richard Prayson3Varun Kshettry4Pablo Recinos5Betul Hatipoglu6Kevin M. Pantalone7Robert Weil8Amir H. Hamrahian9Laurence Kennedy10Divya Yogi-Morren11Department of Endocrinology, Diabetes and Metabolism, Cleveland ClinicDepartment of Endocrinology, Diabetes and Metabolism, Cleveland ClinicDepartment of Quantitative Health SciencesDepartment of Anatomic Pathology, Cleveland ClinicDepartment of Brain Tumor and Neuro-Oncology Center, Cleveland ClinicDepartment of Brain Tumor and Neuro-Oncology Center, Cleveland ClinicDepartment of Endocrinology, Diabetes and Metabolism, Cleveland ClinicDepartment of Endocrinology, Diabetes and Metabolism, Cleveland ClinicLifespan Physician Group, Rhode Island HospitalDepartment of Endocrinology, Diabetes and Metabolism, Johns Hopkins UniversityDepartment of Endocrinology, Diabetes and Metabolism, Cleveland ClinicDepartment of Endocrinology, Diabetes and Metabolism, Cleveland ClinicAbstract Background To examine the clinical and hormonal profiles, comorbidities, treatment patterns, surgical pathology and clinical outcomes of patients diagnosed with acromegaly at the Cleveland Clinic over a 15-year period. Methods A retrospective chart review of patients with acromegaly who underwent surgical resection between 2003 and 2018. Results A total of 136 patients (62 men; mean age 48.1 years) with biochemical evidence of acromegaly were analyzed. Median insulin-like growth factor 1 (IGF-1) level at diagnosis was 769.0 ng/mL and most patients had a macroadenoma (82.2%). Immunoreactivity to growth hormone (GH) was noted in 124 adenomas, with co-staining in 89 adenomas. Complete visible tumor resection during initial surgery was achieved in 87 patients (64.0%). In this cohort, complete response to surgery alone was observed in 61 patients (70.1%), while 31 out of 65 patients (47.7%) who received additional post-surgical medications and/or radiation therapy achieved complete response. At most recent follow-up, 92 patients achieved eventual complete response by documented normalization of IGF-1 levels. Higher IGF-1 level at diagnosis (P = 0.024) and cavernous sinus invasion (P = 0.028) were predictors for failure to respond to surgery. Conclusion In this study, the majority of tumors were macroadenoma, plurihormonal, and treated effectively with surgery alone or surgery with adjuvant medical or radiation therapy. More studies are needed to identify additional molecular biomarkers, tumor characteristics and imaging findings to individualize treatment and better predict treatment outcomes.http://link.springer.com/article/10.1186/s40842-020-00104-5AcromegalyIGF-1Growth hormonePituitary adenomaSparsely granulated
collection DOAJ
language English
format Article
sources DOAJ
author Lima Lawrence
Kenda Alkwatli
James Bena
Richard Prayson
Varun Kshettry
Pablo Recinos
Betul Hatipoglu
Kevin M. Pantalone
Robert Weil
Amir H. Hamrahian
Laurence Kennedy
Divya Yogi-Morren
spellingShingle Lima Lawrence
Kenda Alkwatli
James Bena
Richard Prayson
Varun Kshettry
Pablo Recinos
Betul Hatipoglu
Kevin M. Pantalone
Robert Weil
Amir H. Hamrahian
Laurence Kennedy
Divya Yogi-Morren
Acromegaly: a clinical perspective
Clinical Diabetes and Endocrinology
Acromegaly
IGF-1
Growth hormone
Pituitary adenoma
Sparsely granulated
author_facet Lima Lawrence
Kenda Alkwatli
James Bena
Richard Prayson
Varun Kshettry
Pablo Recinos
Betul Hatipoglu
Kevin M. Pantalone
Robert Weil
Amir H. Hamrahian
Laurence Kennedy
Divya Yogi-Morren
author_sort Lima Lawrence
title Acromegaly: a clinical perspective
title_short Acromegaly: a clinical perspective
title_full Acromegaly: a clinical perspective
title_fullStr Acromegaly: a clinical perspective
title_full_unstemmed Acromegaly: a clinical perspective
title_sort acromegaly: a clinical perspective
publisher BMC
series Clinical Diabetes and Endocrinology
issn 2055-8260
publishDate 2020-08-01
description Abstract Background To examine the clinical and hormonal profiles, comorbidities, treatment patterns, surgical pathology and clinical outcomes of patients diagnosed with acromegaly at the Cleveland Clinic over a 15-year period. Methods A retrospective chart review of patients with acromegaly who underwent surgical resection between 2003 and 2018. Results A total of 136 patients (62 men; mean age 48.1 years) with biochemical evidence of acromegaly were analyzed. Median insulin-like growth factor 1 (IGF-1) level at diagnosis was 769.0 ng/mL and most patients had a macroadenoma (82.2%). Immunoreactivity to growth hormone (GH) was noted in 124 adenomas, with co-staining in 89 adenomas. Complete visible tumor resection during initial surgery was achieved in 87 patients (64.0%). In this cohort, complete response to surgery alone was observed in 61 patients (70.1%), while 31 out of 65 patients (47.7%) who received additional post-surgical medications and/or radiation therapy achieved complete response. At most recent follow-up, 92 patients achieved eventual complete response by documented normalization of IGF-1 levels. Higher IGF-1 level at diagnosis (P = 0.024) and cavernous sinus invasion (P = 0.028) were predictors for failure to respond to surgery. Conclusion In this study, the majority of tumors were macroadenoma, plurihormonal, and treated effectively with surgery alone or surgery with adjuvant medical or radiation therapy. More studies are needed to identify additional molecular biomarkers, tumor characteristics and imaging findings to individualize treatment and better predict treatment outcomes.
topic Acromegaly
IGF-1
Growth hormone
Pituitary adenoma
Sparsely granulated
url http://link.springer.com/article/10.1186/s40842-020-00104-5
work_keys_str_mv AT limalawrence acromegalyaclinicalperspective
AT kendaalkwatli acromegalyaclinicalperspective
AT jamesbena acromegalyaclinicalperspective
AT richardprayson acromegalyaclinicalperspective
AT varunkshettry acromegalyaclinicalperspective
AT pablorecinos acromegalyaclinicalperspective
AT betulhatipoglu acromegalyaclinicalperspective
AT kevinmpantalone acromegalyaclinicalperspective
AT robertweil acromegalyaclinicalperspective
AT amirhhamrahian acromegalyaclinicalperspective
AT laurencekennedy acromegalyaclinicalperspective
AT divyayogimorren acromegalyaclinicalperspective
_version_ 1724692581479088128